A number of other equities analysts have also recently issued reports on RTTR. Zacks Investment Research upgraded shares of Ritter Pharmaceuticals from a sell rating to a hold rating in a research note on Friday, September 2nd. Maxim Group reiterated a buy rating on shares of Ritter Pharmaceuticals in a research note on Tuesday, June 28th.
Shares of Ritter Pharmaceuticals (NASDAQ:RTTR) opened at 2.30 on Tuesday. The company’s 50-day moving average is $1.60 and its 200-day moving average is $1.55. The stock’s market cap is $19.74 million. Ritter Pharmaceuticals has a 12-month low of $0.98 and a 12-month high of $2.63.
Ritter Pharmaceuticals (NASDAQ:RTTR) last announced its earnings results on Monday, August 8th. The company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.14. On average, equities research analysts anticipate that Ritter Pharmaceuticals will post ($1.38) earnings per share for the current year.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
Receive News & Ratings for Ritter Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.